BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 1
• 2
• 3
• 4
• 5
• 7
• 8
• 9
• 10
• 11
• 12
• 14
• 15
• 16
• 17
• 18
• 19
• 21
• 22
• 23
• 24
• 25
• 26
• 28
• 29
• 30

• Press Releases

  LEM Surgical Announces second FDA 510(k) Clearance for Next-Generation Humanoid Robotic Surgical System

  June 23, 2026

   · 

  2 min read
• Press Releases

  QuidelOrtho Appoints Micah Young as Chief Financial Officer

  June 23, 2026

   · 

  3 min read
• Press Releases

  NS Pharma Parent Company, Nippon Shinyaku, Announces Sponsored Research Agreement with Boston Children’s Hospital

  June 23, 2026

   · 

  1 min read
• Press Releases

  Mediar Therapeutics Announces First Cohorts Dosed in Phase 1 Clinical Trial of MTX-439 for Fibrosis Associated with Chronic Kidney Disease (CKD) and Additions to Clinical Advisory Board

  June 23, 2026

   · 

  5 min read
• Press Releases

  Access Vascular and Medline Enter Multi-Year Agreement to Launch Cobranded Next-Generation Vascular Access Catheters

  June 23, 2026

   · 

  4 min read
• Press Releases

  Veristat Strengthens Biostatistics, Drug Development Advisory, and People Leadership to Support Growth in Complex Clinical Development

  June 23, 2026

   · 

  4 min read
• Press Releases

  Genetix Biotherapeutics and SPIMACO Announce Strategic Agreement to Commercialize and Manufacture LYFGENIA™ & ZYNTEGLO™ in Saudi Arabia and the Broader Middle East Region

  June 23, 2026

   · 

  14 min read
• Press Releases

  Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026

  June 23, 2026

   · 

  5 min read
• Press Releases

  Syntax Bio and Applied StemCell Announce Strategic Collaboration to Advance Stem Cell Innovation

  June 23, 2026

   · 

  3 min read
• 

  Lung cancer

  Pfizer delivers ‘disappointing’ late-stage lung cancer data for ADC from $43B Seagen buy

  Despite an overall survival miss, Leerink Partners said Pfizer’s antibody-drug conjugate showed “promising” signals of efficacy in a subgroup of patients who had undergone only one prior line of treatment.

  June 23, 2026

   · 

  2 min read

   · 

  Tristan Manalac